← Back to Search

2 for Breast Cancer

Phase 2
Waitlist Available
Led By Sam Wiseman, MD, FRCSC, FACS
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

The purpose of this study is to map the arm lymphatic drainage system in the axilla with blue dye and the breast drainage system with a radioactive material. By identifying the arm lymphatics they can be protected during surgery and this may decrease the occurrence of lymphedema. The information obtained in this study may provide us with better surgical techniques to identify and protect the arm lymphatic drainage system in the axilla.

Eligible Conditions
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Active Control
Group I: 2Active Control1 Intervention
Each patient will receive an injection of technetium-99m sulfur colloid directed subareolar or around the tumor. The material will be prepared as per manufacturer's specifications. The dose will be 20mBq given the same day of 80mBq given the day before. The Nuclear Medicine Department at St Paul's Hospital will perform the injection as per normal sentinel lymph node mapping protocol.
Group II: 1Active Control1 Intervention
Each patient will receive an injection of technetium-99m sulfur colloid directed subareolar or around the tumor. The material will be prepared as per manufacturer's specifications. The dose will be 20mBq given the same day of 80mBq given the day before. The Nuclear Medicine Department at St Paul's Hospital will perform the injection as per normal sentinel lymph node mapping protocol.

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,451 Previous Clinical Trials
2,483,090 Total Patients Enrolled
13 Trials studying Breast Cancer
2,945 Patients Enrolled for Breast Cancer
Urve Kuusk, MD, FRCSCStudy DirectorUniversity of British Columbia
Carolyne Dingee, MD,FRCSCStudy DirectorUniversity of British Columbia
~8 spots leftby Sep 2025